Recommended Dose: Standard dosage regimen: 500 mg intramuscular injection on Day 1, 15, 29, then once every 28 days thereafter. Each administration consists of two 250 mg injections, one into each gluteal muscle. No dose reduction required for elderly patients, mild to moderate liver/renal dysfunction.

Time: Initial booster shots at Day 1, 15, 29; maintenance injection every 4 weeks permanently until disease progression or intolerable toxicity.

Interaction: Co-administration of estrogen agents will neutralize anti-tumor activity, strictly forbidden. No significant drug-drug interaction with common chemotherapy, targeted medicines. No dose adjustment needed when combined with CDK4/6 inhibitors.

Side effects: Common reactions: Injection site pain, hot flushes, arthralgia, fatigue, nausea, headache, rash, diarrhea. Long-term risks: Osteopenia, elevated fracture risk, transient liver enzyme elevation, venous thromboembolism. Rare severe adverse events: Hypersensitivity reactions, vaginal hemorrhage.